Voclosporin Granted Priority Review for Lupus Nephritis

click here
<pre></pre>

 

The Food and Drug Administration (FDA) will give Priority Review to the New Drug Application (NDA) of voclosporin (Aurinia Pharmaceuticals) for the treatment of lupus nephritis.

Voclosporin, a novel calcineurin inhibitor, works by blocking interleukin (IL)-2 expression and T-cell mediated immune responses and stabilizing the podocyte in the kidney. The NDA is supported by data from the pivotal phase 3 AURORA and phase 2 AURA-LV studies.

https://www.biospace.com/article/releases/aurinia-announces-u-s-food-and-drug-administration-acceptance-of-the-filing-of-new-drug-application-and-priority-review-for-voclosporin-for-the-treatment-of-lupus-nephritis/